Meet Max, living with Duchenne Muscular Dystrophy
At Entrada, we are driven to transform the lives of patients by establishing a new class of intracellular therapeutics
November 6, 2025
Entrada Therapeutics Reports Third Quarter 2025 Financial Results
October 28, 2025
Entrada Therapeutics to Present at Upcoming Investor Conferences
Our Platform
Our proprietary EEV™ Platform has the potential to reach and engage previously inaccessible and undruggable disease-causing targets within cells.
Our Clinical Studies
At Entrada we are united in our mission to treat devastating diseases with intracellular therapeutics — including Duchenne muscular dystrophy.
Our Pipeline
Our EEV™ Platform is highly versatile and modular, offering broad potential across therapeutic areas. We are developing potential treatments spanning discovery to clinical-stage across retinal, neuromuscular and metabolic diseases, and this is just the beginning.
Life at Entrada
Innovation isn’t easy, and we’re up for the challenge. Are you?